Prophylactic central neck dissection for cN0 papillary thyroid carcinoma: is there any difference between western countries and China? A systematic review and meta-analysis

Background Recommendations for the performance of prophylactic central neck dissection (pCND) in patients with clinically node-uninvolved (cN0) papillary thyroid carcinoma (PTC) are not the same. This meta-analysis set out to compare the effectiveness of pCND with total thyroidectomy (TT) in different countries and regions, mainly between western countries and China. Methods The electronic databases PubMed, EMBASE, and Cochrane Library were searched for studies published until August 2022. The incidence rate of cervical lymph node metastases (LNMs), locoregional recurrences (LRRs), and postoperative complications were pooled by a random-effects model. Subgroup analyses based on different countries and regions were performed. Results Eighteen studies involving 5,346 patients were analyzed. In the subgroup of western countries, patients undergoing pCND with TT had a significantly lower LRR rate [69/1,804, 3.82% vs. 139/2,541, 5.47%; odds ratio (OR) = 0.56; 95% CI 0.37–0.85] and a higher rate of temporary hypoparathyroidism (HPT) (316/1,279, 24.71% vs. 194/1,467, 13.22%; OR = 2.23; 95% CI 1.61–3.08) than that of the TT alone group, while no statistically significant difference was found in the rate of permanent HPT and temporary and permanent recurrent laryngeal nerve (RLN) injury. In the Chinese subgroup, the pCND with TT group had a significantly higher incidence rate of both temporary HPT (87/374, 23.26% vs. 36/324, 11.11%; OR = 2.24; 95% CI 1.32–3.81) and permanent HPT (21/374, 5.61% vs. 4/324, 1.23%; OR = 3.58; 95% CI = 1.24–10.37) than that of the TT alone group, while no significant difference was detected in the rate of LRR and temporary and permanent RLN injury. Conclusion Compared with the TT alone for cN0 PTC patients, pCND with TT had a significantly lower LRR rate while having a higher temporary HPT rate in Europe, America, and Australia; however, it showed no significant difference in decreasing LRR rate while having a significantly raised rate of temporary and permanent HPT in China. More population-based results are required to advocate precision medicine in PTC. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022358546.

[1]  A. Sanabria,et al.  Prophylactic Central Neck Lymph Node Dissection in Low-risk Thyroid Carcinoma Patients Does Not Decrease the Incidence of Locoregional Recurrence , 2022, Annals of surgery.

[2]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[3]  Yan Luo,et al.  Duration of Parathyroid Function Recovery in Patients With Protracted Hypoparathyroidism After Total Thyroidectomy for Papillary Thyroid Carcinoma , 2021, Frontiers in Endocrinology.

[4]  Hui Huang,et al.  Evaluating the risk of re-recurrence in patients with persistent/recurrent thyroid carcinoma after initial reoperation. , 2020, Surgery.

[5]  David F. Schneider,et al.  A Randomized Controlled Clinical Trial , 2020, Annals of Surgery.

[6]  M. Papotti,et al.  Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  S. Roman,et al.  Geographic influences in the global rise of thyroid cancer , 2019, Nature Reviews Endocrinology.

[8]  Wenshuang Wu,et al.  Does the number of parathyroid glands autotransplanted affect the incidence of hypoparathyroidism and recovery of parathyroid function? , 2018, Surgery.

[9]  E. Loh,et al.  Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma with Clinically Uninvolved Central Neck Lymph Nodes: A Systematic Review and Meta-analysis , 2018, World Journal of Surgery.

[10]  I. Leuchter,et al.  Modification of the Surgical Strategy for the Dissection of the Recurrent Laryngeal Nerve Using Continuous Intraoperative Nerve Monitoring , 2018, World Journal of Surgery.

[11]  S. Sidhu Modification of the Surgical Strategy for the Dissection of the Recurrent Laryngeal Nerve Using Continuous Intraoperative Nerve Monitoring , 2018, World Journal of Surgery.

[12]  Z. Lina,et al.  Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer , 2017, Nuclear medicine communications.

[13]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[14]  Zhihui Li,et al.  Carbon nanoparticles facilitate lymph nodes dissection and parathyroid glands identification in reoperation of papillary thyroid cancer , 2017, Medicine.

[15]  N. Liao,et al.  An updated meta-analysis , 2017 .

[16]  S. Piana,et al.  Long-term outcomes of central neck dissection for cN0 papillary thyroid carcinoma. , 2017, American journal of otolaryngology.

[17]  Wan-jun Zhao,et al.  Evaluating the effectiveness of prophylactic central neck dissection with total thyroidectomy for cN0 papillary thyroid carcinoma: An updated meta-analysis. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  Yi Pan,et al.  2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma , 2017, Cancer biology & medicine.

[19]  L. You,et al.  The Effect of Prophylactic Central Neck Dissection on Locoregional Recurrence in Papillary Thyroid Cancer After Total Thyroidectomy: A Systematic Review and Meta-Analysis , 2017, Annals of Surgical Oncology.

[20]  B. Fabris,et al.  Rationality in prophylactic central neck dissection in clinically node-negative (cN0) papillary thyroid carcinoma: Is there anything more to say? A decade experience in a single-center. , 2017, International journal of surgery.

[21]  C. Lombardi,et al.  Role of prophylactic central neck dissection in clinically node-negative differentiated thyroid cancer: assessment of the risk of regional recurrence , 2017, Updates in Surgery.

[22]  A. Miyauchi,et al.  Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[23]  Jingqiang Zhu,et al.  Preoperative ultrasound-guided carbon nanoparticles localization for metastatic lymph nodes in papillary thyroid carcinoma during reoperation , 2017, Medicine.

[24]  E. Tatar,et al.  The need of prophylactic central lymph node dissection is controversial in terms of postoperative thyroglobulin follow-up of patients with cN0 papillary thyroid cancer , 2017, Langenbeck's Archives of Surgery.

[25]  P. Glasziou,et al.  Prevalence of Differentiated Thyroid Cancer in Autopsy Studies Over Six Decades: A Meta-Analysis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[27]  M. Kammori,et al.  Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients. , 2015, Endocrine journal.

[28]  Qingsi He,et al.  Clinical risk factors for central lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta‐analysis , 2015, Clinical endocrinology.

[29]  Ziwen Liu,et al.  The clinical prognosis of patients with cN0 papillary thyroid microcarcinoma by central neck dissection , 2015, World Journal of Surgical Oncology.

[30]  S. Lam,et al.  Complication rates of central compartment dissection in papillary thyroid cancer , 2015, ANZ journal of surgery.

[31]  Chieh-Hsi Wu,et al.  A population‐based nested case–control study: the use of 5‐alpha‐reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia , 2015, Clinical endocrinology.

[32]  P. Vitti,et al.  Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. , 2015, The Journal of clinical endocrinology and metabolism.

[33]  L. Gordini,et al.  Total thyroidectomy without prophylactic central neck dissection in clinically node-negative papillary thyroid cancer: is it an adequate treatment? , 2014, World Journal of Surgical Oncology.

[34]  M. Schlumberger,et al.  Influence of Prophylactic Neck Dissection on Rate of Retreatment for Papillary Thyroid Carcinoma , 2013, World Journal of Surgery.

[35]  M. Barczyński,et al.  Prophylactic central neck dissection for papillary thyroid cancer , 2013, The British journal of surgery.

[36]  C. Lombardi,et al.  Prospective evaluation of total thyroidectomy versus ipsilateral versus bilateral central neck dissection in patients with clinically node-negative papillary thyroid carcinoma. , 2012, Surgery.

[37]  Wei Zhang,et al.  Routine central neck dissection in differentiated thyroid carcinoma: A systematic review and meta‐analysis , 2012, The Laryngoscope.

[38]  M. Willingham,et al.  SKI-606, an Src Inhibitor, Reduces Tumor Growth, Invasion, and Distant Metastasis in a Mouse Model of Thyroid Cancer , 2012, Clinical Cancer Research.

[39]  K. Schulte,et al.  Central cervical lymph node metastases in papillary thyroid cancer: a systematic review of imaging‐guided and prophylactic removal of the central compartment , 2012, Clinical endocrinology.

[40]  Kevin Ro,et al.  A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. , 2011, Surgery.

[41]  B. Lang,et al.  Impact of Routine Unilateral Central Neck Dissection on Preablative and Postablative Stimulated Thyroglobulin Levels after Total Thyroidectomy in Papillary Thyroid Carcinoma , 2011, Annals of surgical oncology.

[42]  R. Burney,et al.  Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. , 2010, Surgery.

[43]  A. Stang Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.

[44]  G. Pentheroudakis,et al.  Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  T. Fahey,et al.  Impact of Prophylactic Central Neck Lymph Node Dissection on Early Recurrence in Papillary Thyroid Carcinoma , 2010, World Journal of Surgery.

[46]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[47]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.

[48]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[49]  L. Rotstein The role of lymphadenectomy in the management of papillary carcinoma of the thyroid , 2009, Journal of surgical oncology.

[50]  F. Schmidt Meta-Analysis , 2008 .

[51]  P. Trimboli,et al.  Trend in thyroid carcinoma size, age at diagnosis, and histology in a retrospective study of 500 cases diagnosed over 20 years. , 2006, Thyroid : official journal of the American Thyroid Association.

[52]  C. Orlandini,et al.  Randomized controlled trial of harmonic scalpel use during thyroidectomy. , 2006, Archives of otolaryngology--head & neck surgery.

[53]  P. Hall,et al.  Clinically significant prognostic factors for differentiated thyroid carcinoma , 2006, Cancer.

[54]  J. Jimeno,et al.  Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. , 2005, Surgery.

[55]  J. Chan,et al.  Papillary microcarcinoma of the thyroid—Prognostic significance of lymph node metastasis and multifocality , 2003, Cancer.

[56]  K. Hatakeyama,et al.  Do the level of nodal disease according to the TNM classification and the number of involved cervical nodes reflect prognosis in patients with differentiated carcinoma of the thyroid gland? , 1998, Journal of surgical oncology.

[57]  T. Defechereux,et al.  Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma , 1998, Langenbeck's Archives of Surgery.

[58]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[59]  S. Jhiang,et al.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.

[60]  Jun Ren,et al.  A retrospective cohort study , 2021 .

[61]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[62]  Kaliszewski,et al.  American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer , 2017 .

[63]  P. Haigh,et al.  Preferential Use of Total Thyroidectomy without Prophylactic Central Lymph Node Dissection for Early-Stage Papillary Thyroid Cancer: Oncologic Outcomes in an Integrated Health Plan. , 2016, The Permanente journal.